Tele: 561.316.3330
Breaking Medical Device News

Thursday, October 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeFUNDINGNeuspera Medical Announces Final Close of $26M Series B Equity Financing

Neuspera Medical Announces Final Close of $26M Series B Equity Financing

Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the final closing (2nd tranche) of the company’s Series B equity financing.

Neuspera Medical reports the final $12 million dollar tranche of the total $26 million round was triggered upon fulfillment of pre-defined product development and regulatory program objectives.  Each of the original Series B investors participated in the 2nd tranche – including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta Capital, LLC, Purple Arch Ventures and others.  The proceeds will be used to advance the Company’s clinical programs for its implantable neuromodulation technology platform.

Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronics medicines.  Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than neuromodulation devices using a traditional implanted battery power source and may reduce implant procedure complexity, patient complication, and post-surgical pain.

“The Neuspera team has executed well against its milestones for this final tranche of funding for Series B,” said Dr. Zhu, Managing Partner of 6 Dimensions Capital.  “We continue to see the Neuspera platform as an important conduit to bringing the benefits of implantable medical device treatments to patients suffering from many chronic diseases earlier in their treatment cycle.”

“We have been keeping pace with our primary objective to bring forward the beneficial outcomes of neuromodulation treatment to more patients struggling with chronic and debilitating diseases,” said Milton M. Morris, Ph.D., President & CEO of Neuspera.  “We continue to see broad support and interest in our program as we effort to bring this technology forward to improve patient care and outcomes.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy